41
Tikal Kansara Baroda Medical College (BMC)

Myasthenia gravis

Embed Size (px)

DESCRIPTION

My 1st presentation in B J Medical College. Dr. VCS Unit. It was fun.

Citation preview

Page 1: Myasthenia gravis

Tikal Kansara

Baroda Medical College (BMC)

Page 2: Myasthenia gravis

MYASTHENIA GRAVIS

Photo Courtesy - http://www.beverlyhillsneurology.com/myastheniagravis-symptoms.html

Page 3: Myasthenia gravis

Myasthenia Gravis

Myasthenia Gravis (MG) is a neuromuscular disorder characterized by weakness and fatigability of skeletal muscles.

Key Concept :- It is due to the decrease in the number of available

acetylcholine receptors (AchRs) at neuromuscular junctions due to antibody mediated autoimmune attack.

Page 4: Myasthenia gravis

Myasthenia Gravis

Epidemiology Pathophysiology Clinical Features Diagnosis Treatment

Page 5: Myasthenia gravis

EPIDEMIOLOGY

Highest prevalence rate is 20.4 per 100,000 population.1

Prevalence of disease is increasing since 1950s. 2,3

Improved recognitionHigh sensitivity & specificity of the test.

Longer life-span due to effective treatment More people in the ‘at risk’ group due to

increased life expectancy.

Page 6: Myasthenia gravis

Currently, there are 60,000 patients with myasthenia gravis in Unites States.2

The incidence & prevalence increases substantially after the age of 55 years.4,5

The chances of “only ocular disease” increases after the age of 55 years.6

Atypical presentation :- Weakness in the distal extremity. Different immunological & electrophysiological findings. Prevalence 7% of patients.7

Page 7: Myasthenia gravis

PATHOPHYSIOLOGY

Autoimmune channelopathy Genetic predisposition:

HLA B8 & DR3 DR1 specific for ocular myasthenia

75% patients have abnormality of thymus 10% have thymoma.

Page 8: Myasthenia gravis

Autoantibodies against nicotinic acetylcholinrereceptors (nAchRs)

These antibodies prevent binding of Ach to its receptors

Other action: Destruction of receptors

By complement activationElimination by endocytosis

Page 9: Myasthenia gravis

B- cells converts to plasma cells

Production of antibodies

SYMPTOMS

Page 10: Myasthenia gravis

http://jama.ama-assn.org/content/298/1/29/embed/graphic-1.jpg

Page 11: Myasthenia gravis
Page 12: Myasthenia gravis

CLINICAL FEATURES

Fluctuation weakness increasing trough the day & relieved by rest.

Extra ocular muscle weakness Present in 50% of patients initially. Present in 90% of patients during the course of disease. Disease remains ocular in 16% of patients.

Page 13: Myasthenia gravis

Ocular Symptoms

Usually affects one extra ocular muscle Ptosis Not limited by innervations of one cranial nerve Limited adduction of one eye with nystagmus of the

abducting eye on attempted lateral gaze Diplopia common. Sclera below limbus may be visible due to weak

lower eyelid.

Page 15: Myasthenia gravis

Respiratory Symptoms

Weakness of intercostal muscles and diaphragm may lead to CO2 retention

Weakness of pharyngeal muscles may collapse the airway.

O2 saturation can be normal while CO2 is retained. So, pulse oximetry is not reliable to detect the amount of paralysis.

Page 16: Myasthenia gravis

Other symptoms

Palatal muscle weakness Nasal voice Nasal regurgitation

Swallowing may be difficult & regurgitation of foods can occur. Coughing & choking while drinking.

Limb weakness can also be present Initially proximal but may follow distal muscles also.

Page 17: Myasthenia gravis

CO-EXISTING AUTOIMMUNE DISEASES

Hyperthyroidism Weakness may not improve simply by treatment of

patients with MG; with co-existing hyperthyroidism. Rheumatoid arthritis Scleroderma Lupus

Page 18: Myasthenia gravis

TYPES OF MYASTHENIA GRAVIS NEONATAL: In 12% of the pregnancies with a mother with MG,

she passes the antibodies to the infant through the placenta, causing neonatal myasthenia gravis. The symptoms will start in the first two days and disappear within a few weeks after birth. With the mother, it is not uncommon for the symptoms to even improve during pregnancy, but they might worsen after labor.

CONGENITAL: Children of a healthy mother can, very rarely, develop myasthenic symptoms beginning at birth, congenital myasthenic syndrome or CMS. Other than myasthenia gravis, CMS is not caused by an autoimmune process, but due to synaptic malformation, which in turn is caused by genetic mutations. Thus, CMS is a hereditary disease. More than 11 different mutations have been identified, and the inheritance pattern is typically autosomal recessive.

JUVENILE: myasthenia occurring in childhood, but after the peripartum period

Page 19: Myasthenia gravis

DIAGNOSIS

Physical examination Blood tests Neurophysiology Edrophonium test Imaging techniques Pulmonary function tests

Page 20: Myasthenia gravis

Physical Examination

Looking upwards & sidewards for 30 seconds For diplopia & ptosis

Looking at the feet while lying on the back for 30 seconds

Keeping arms stretched forward for 60 seconds Ten deep knee bends Wallking 30 steps on both the toes & heels “Peek Sign” – After initial apposition of lid margins,

they quickly start to separate (in 30 seconds) & the sclera start to show.

Page 21: Myasthenia gravis

Photo Courtesy - http://www.eacog.org/2011/06/myasthenia-gravis-photos-and-pictures/

Page 22: Myasthenia gravis

Blood Tests

Detection of acetylcholine receptor antibodies. Sensitivity of 80-96% 50% of patients with only ocular disease may lack in these

antibodies In some cases, anti-MuSK protein antibodies. Antibodies against voltage-gated calcium channels

to differenciate from Lambert-Eaton Myasthenic Syndrome (LEMS).

Page 23: Myasthenia gravis

Neurophysiology

Repetitive nerve stimulation test. Electromyography.

Page 24: Myasthenia gravis

Edrophonium Test

More used to differenciate myasthenic crises from cholinergic crises.Paralysed Muscle

Edrophonium Chloride

Myasthenic Crises

Temporary Improvement

Cholinergic Crises

No improvement

Page 25: Myasthenia gravis

Video Courtesy - <object width="960" height="750"><param name="movie" value="http://www.youtube.com/v/k7YX9kuWrxA?version=3&amp;hl=en_US"></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="http://www.youtube.com/v/k7YX9kuWrxA?version=3&amp;hl=en_US" type="application/x-shockwave-flash" width="960" height="750" allowscriptaccess="always" allowfullscreen="true"></embed></object>

Page 26: Myasthenia gravis

Imaging

Chest X-Ray Detection of thymoma. To detect lung cancer for alternate diagnoses i.e. lambert-

Eaton Syndrome. CT-Scan MRI Scan

Page 29: Myasthenia gravis

Pulmonary Function Tests

Forced Vital Capacity is monitored to detect any gradual loss of respiratory functions.

Negative inspiratory force is useful to detect adequacy of ventilation.

Page 30: Myasthenia gravis

Immunoflourescence

To detect IgG antibodies against neuromuscular junction.

Page 31: Myasthenia gravis

Classification of myasthenia gravis6

Class I: Any eye muscle weakness, possible ptosis, no other evidence of muscle weakness elsewhere

Class II: Eye muscle weakness of any severity, mild weakness of other muscles Class IIa: Predominantly limb or axial muscles Class IIb: Predominantly bulbar and/or respiratory muscles

Class III: Eye muscle weakness of any severity, moderate weakness of other muscles Class IIIa: Predominantly limb or axial muscles Class IIIb: Predominantly bulbar and/or respiratory muscles

Class IV: Eye muscle weakness of any severity, severe weakness of other muscles Class IVa: Predominantly limb or axial muscles Class IVb: Predominantly bulbar and/or respiratory muscles (Can also include

feeding tube without intubation) Class V: Intubation needed to maintain airway

Page 32: Myasthenia gravis

TREATMENT

AchE Inhibitors Immunomodulatory Therapies Plasma Exchange Thymectomy

Page 33: Myasthenia gravis

AchE Inhibitors

Pyridostigmine Bromide - Starts in 30-60 mins & effect lasts 3-6 hours Caution for cholinergic crises.

Page 34: Myasthenia gravis

Corticosteroids

Most commonly used corticosteroid in US Significant improvement is often seen after a

decreased antibody titer which is usually 1-4 months  No single dose regimen is accepted

Some start low and go high Others start high dose to achieve a quicker response

Clearance may be decreased by estrogens or digoxin Patients taking concurrent diuretics should be

monitored for hypokalemia

Page 35: Myasthenia gravis

Immunomodulatory Drugs

Drugs that alter the immune response can be used. Commonly used drugs are

Azathioprine Cyclosporine Mycophenolate

Page 36: Myasthenia gravis

Therapies

Plasmapheresis Filters out the antibodies from blood Effect lasts only for a few weeks.

IV immuneglogulin Provides body with antibodies Binds to circulating antibodies.

Page 37: Myasthenia gravis

Surgery

Thymectomy Surgical removal of thymus.

Page 38: Myasthenia gravis

Behavioral Modifications

Diet Thickened liquids are preferred, when dysphagia arises to

counteract the fear of aspiration. Asparagus should be taken as it contains steroid-like

substance. Activity

Patients should be as active as possible but should take rest in between.

Yoga exercises to stretch the weakened muscles should be done.

This not only strengthens the muscles but also provides oxygen & removes carbon dioxide from them.

Page 39: Myasthenia gravis

Research Paper References

1. Isbister CM, Mackenzie PJ, Anderson D, et al. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia: a population-based study [abstract]. Neurology 2002;58(suppl 3):A185-A186

2. Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003;998:407-412

3. Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996;47:1233-1238

4. Kalb B, Matell G, Pirskanen R, Lambe M. Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden. Neuroepidemiology 2002;21:221-225

5. Phillips LH, Torner JC, Anderson MS, et al. The epidemiology of myasthenia gravis in central and western Virginia. Neurology 1992;42:1888-1893

6. Jaretzke A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000;55:16-23

7. Werner P, Kiechl S, Löscher S, et al. Distal myasthenia gravis: frequency and clinical course in a large prospective series. Acta Neurol Scand 2003;108:209-210

Page 40: Myasthenia gravis

e-References Epidemiology :-

http://www.medscape.com/viewarticle/482694 Pathophysiology

http://en.wikipedia.org/wiki/Myasthenia_gravis#cite_note-5 Clinical Features

http://estudiantesdemedicina.wordpress.com/ Diagnosis

http://en.wikipedia.org/wiki/Myasthenia_gravis#cite_note-5 Treatment

http://estudiantesdemedicina.wordpress.com/ http://www.slideshare.net/drshama65/mysthenia-gravisppt

Page 41: Myasthenia gravis

TIKAL KANSARA

INTERNCIVIL HOSPITAL

AHMEDABAD